Advertisement
Screener

Septerna, Inc. (SEPN) Graph

SEPN Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue $26.75M; Research and development $35.13M; Operating expenses $43.58M; Income tax $973.00K.
  • 2026-03-31: Revenue $26.52M; Research and development $29.54M; Operating expenses $39.82M; Income tax $337.00K.
  • 2025-12-31: Revenue $24.12M*; Research and development $31.86M*; Operating expenses $40.14M*; Income tax $12.00K*.
  • 2025-09-30: Revenue $21.50M; Research and development $24.26M; Operating expenses $18.88M; Income tax $0.00.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$26.75M$35.13M$43.58M$973.00K-$13.03M
2026-03-31$26.52M$29.54M$39.82M$337.00K-$8.64M
2025-12-31$24.12M*$31.86M*$40.14M*$12.00K*-$10.74M*
2025-09-30$21.50M$24.26M$18.88M$0.00$8.17M
2025-06-30$119.00K$22.19M$29.10M$0.00-$24.84M
2025-03-31$219.00K$19.27M$26.13M$0.00-$21.48M
2024-09-30$176.00K$17.83M$22.73M-$136.00K-$20.52M
2024-06-30$370.00K$15.04M$18.43M$109.00K-$16.51M
2024-03-31$317.00K$13.15M$15.81M$93.00K-$14.10M
2023-09-30$33.00K$9.28M$12.07M(m)-$10.95M
2023-06-30(m)(m)(m)(m)-$10.60M
2023-03-31(m)(m)(m)(m)-$9.17M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$53.27M$64.67M$83.41M$1.31M-$21.67M
2025-06-30$338.00K$41.46M$55.23M$0.00-$46.31M
2024-06-30$687.00K$28.19M$34.24M$202.00K-$30.61M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$21.83M$65.72M$74.11M$0.00-$38.14M
2024-09-30$863.00K$46.02M$56.97M-$338.00K-$51.13M
2023-09-30$33.00K$25.65M$32.27M(m)-$30.71M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$45.95M$97.58M$114.25M$12.00K-$48.88M
2024-12-31$1.07M$65.34M$81.90M-$498.00K-$71.80M
2023-12-31$151.00K$35.98M-$1.92M$691.00K$4.18M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xencor Inc (XNCR)United States$1.776B-7.33
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82